(c) 2024 PillSync.com

Sucralfate 1 g

INDICATIONS AND USAGE Sucralfate tablets, USP are indicated in: Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.

Teva Pharmaceuticals USA Inc

FDA Reported Adverse Reactions
[1] drug ineffective    [2] nausea    [3] fatigue    [4] pain    [5] diarrhoea    [6] headache    [7] dyspnoea    [8] vomiting    [9] arthralgia    [10] rash   

5 years ago OVAL WHITE TEVA 2210 Sucralfate 1 g

OVAL WHITE TEVA 2210

5 years ago OVAL WHITE TEVA 2210 Sucralfate 1 g

TEVA 2210 OVAL WHITE

HOW SUPPLIED

SUCRALFATE tablets, USP are available as white, capsule-shaped, biconvex, scored tablets, debossed “TEVA” on one side, and “22” and “10” on the scored side, containing 1 gram of

SUCRALFATE USP, packaged in bottles of 90 (NDC 0093-2210-98), 100 (NDC 0093-2210-01) and 500 (NDC 0093-2210-05) tablets. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Manufactured In Croatia By: PLIVA HRVATSKA d.o.o. Zagreb, Croatia Manufactured For: TEVA PHARMACEUTICALS USA, INC. North Wales, PA 19454 Rev. L 9/2015


More pills like OVAL TEVA 2210

Related Pills

Sucralfate 1 g

Teva Pharmaceuticals USA Inc

Sucralfate 1 g

Teva Pharmaceuticals USA Inc

Sucralfate 1 g

Teva Pharmaceuticals USA Inc












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site